Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.330
-0.050 (-3.62%)
Mar 6, 2026, 4:00 PM EST - Market closed
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$41,280
Profits / Employee
-$846,677
Market Cap
154.63M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Karyopharm Therapeutics | 228 |
| Innate Pharma | 174 |
| Zentalis Pharmaceuticals | 166 |
| Rani Therapeutics Holdings | 106 |
| Artiva Biotherapeutics | 106 |
| Immunic | 90 |
| Milestone Pharmaceuticals | 33 |
FATE News
- 2 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 19 days ago - IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewsWire
- 3 months ago - Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 months ago - Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - GlobeNewsWire
- 7 months ago - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 9 months ago - Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - GlobeNewsWire